MedTrace Logo

Psychological Vulnerabilities and Transgender Adolescents: A Descriptive Epidemiology Study

NCT05126134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2022-07-29

No results posted yet for this study

Summary

The number of adolescents engaging in a transidentity journey has been increasing rapidly over the last decade. However, the knowledge of the medical world concerning the specificities of these adolescents is still too little in France. The objective of this study is to refine the knowledge of the different health care providers who are brought to meet these adolescents. This research proposes to study more specifically the register of psychological vulnerabilities: to cite only a few examplesThese include disorders such as depression, anxiety disorders and eating disorders, all of which cause suffering and difficulties in everyday life. A better understanding of the presence or absence and the distribution of these different types of vulnerabilities among transgender adolescents would allow, among other things, to promote their their screening by health care providers. This better screening would allow doctors to physicians to offer targeted treatment for these disorders in parallel with the transition process. transition process.

Conditions

  • Gender Dysphoria, Adolescent

Interventions

DIAGNOSTIC_TEST

KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)

completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Sophie Çabal-Berthoumieu, MD · University Hospital, Toulouse

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-26
Primary Completion
2022-06-03
Completion
2022-06-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05126134 on ClinicalTrials.gov